Semax peptide is a synthetic heptapeptide derived from the ACTH(4–10) fragment of adrenocorticotropic hormone (ACTH) and has been approved in Russia and other countries for adjuvant therapy in the acute phase of stroke and for cognitive impairment. Its core characteristic is the upregulation of neurotrophic and anti-inflammatory/antioxidant pathways through the melanocortin receptor axis (mainly MC4R), demonstrating neuroprotective and pro-plasticity effects in animal and early clinical studies.
Shaanxi Medibridge supplies 99.5% purity Semax powder for cutting‑edge research. Produced under strict QC with HPLC/MS verification, our RUO-grade Semax (MEHFPGP) delivers consistent performance, excellent solubility, and reliable batch-to-batch reproducibility. Customize labeling and formulation on request. Choose Medibridge for trusted quality, responsive service, and dependable results in neuroprotection and neuroplasticity studies.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Semax |
80714-61-0 |
MB2509251520 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2025-09-25 |
2025-09-26 |
2027-09-24 |
|
Sample Qty Base |
Packing |
Test Method |
|
40.32 KGS |
25Gs/BOTTLE |
HPLC |
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.76% |
|
Peptide Assay |
≥80% |
91.52% |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
salt |
<5.0% |
1.65% |
|
Water |
≤9.0% |
3.01% |
|
Residual Solvent: |
||
|
Methanol |
≤0.3% |
Complies |
|
Isopropanol |
≤0.5% |
Complies |
|
Acetonitrile |
≤0.041% |
0.019% |
|
Methylene Chloride |
≤0.06% |
0.026% |
|
N,N-Dimethylformamide |
≤0.088% |
N.D. |
|
Triethylamine |
≤0.032% |
N.D. |
|
Tert-butyl methyl ether |
≤0.5% |
0.203% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Specifications (for research use only)
Our advantages
1. Purity: HPLC ≥99.5%; identity confirmed by LC‑MS/MS; full COA
2. Low endotoxin and low‑TFA/acetate salt options
3. Optimized lyophilization: rapid dissolution, minimal adsorption
4. Tight batch consistency with defined release specs and retention samples
5. Customization: pack sizes, labeling, amidation, fluorescent/biotin tags
6. Application support: MC4R–cAMP/ERK–BDNF axis protocols on request
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.51% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Scientific Mechanisms and Research Progress (For Academic Exchange Only)
Mechanism of Action
Briefly: Semax peptide is an ACTH fragment-derived peptide whose core characteristics include promoting the expression of neurotrophic factors (such as BDNF), enhancing synaptic plasticity, and regulating oxidative stress and neuroinflammation. Research primarily originates from the fields of stroke, brain injury, and cognitive function in Russia/Eastern Europe.
a.Receptors and Upstream Signaling: Primarily the melanocortin receptor axis, with a focus on MC4R; initiating cAMP/PKA signaling.
b.Key Signaling Pathways: ERK/MAPK and PI3K/Akt have been consistently observed to be activated; downstream, they influence transcription factors such as c-Fos and CREB, promoting neurotrophic factor expression (especially the BDNF/TrkB axis).
c.Glial Cell Role: ERK/c-Fos activation and optimized cytokine profiles are observed in astrocytes, exhibiting an overall anti-inflammatory trend.
d.Antioxidant/Cellular Protection: Possibly via the Nrf2/HO-1 pathway, reducing ROS and lipid peroxidation, alleviating excitotoxicity and ischemia-reperfusion injury.
e.Genetic Level: Transcriptome data show upregulation of gene sets related to synaptic construction/plasticity, inflammation suppression, and axonal repair.
a.In vitro: In neuronal/glial cell models, increased survival rate, BDNF secretion, and ERK phosphorylation, and decreased inflammatory and oxidative stress markers.
b.In vivo: Improvements in behavioral and histological endpoints have been repeatedly reported in ischemic stroke (e.g., MCAO), TBI, and cognitive impairment models.
c.Current translational status: Pharmaceutical use is observed in Russia and other regions; however, in most countries/regions, it remains primarily a research material, and further research is needed to refine long-term safety and dose-response profiles.
Research Applications and Experimental Suggestions (For Academic Exchange Only)
Application Scenarios and Endpoint Design
a. Neuroprotection/Plasticity: Hypoxia-reoxygenation, glutamate excitotoxicity, oxidative damage models; endpoints include cell survival, synaptic markers, and neurotrophic factor levels.
b. Neuroinflammation: LPS/cytokine stimulation; detection of NF-κB, Nrf2 axis, and inflammatory cytokine profiles (TNF-α, IL-1β, IL-6).
c. Cognition/Behavioral: Water maze, new object recognition, Y-maze, open field, etc.; combining histological (infarct volume, neuron count) and molecular endpoints (BDNF/ERK/Akt/CREB).
d. Omics and Mechanisms: RNA-seq/ATAC-seq, qPCR, WB, ELISA, immunofluorescence; combined with pathway inhibitors and receptor antagonists for mechanism validation.
In vitro usage recommendations (reference range, requires secondary optimization according to the project)
a. Concentration gradient: 10 nM–10 μM; commonly used initial three points: 100 nM, 300 nM, and 1 μM, or a finer gradient of 0.1–1 μM.
b. Treatment duration: Pretreatment 30–60 min; parallel comparison of two strategies: co-treatment with stress or pretreatment followed by stress.
c. Control setup: Equal volume negative control with vector; positive control can be foscorine or exogenous BDNF; mechanism control can be an ERK inhibitor (U0126) or an MC4R antagonist (such as SHU9119).
Precautions
Use low endotoxin batches and low-adsorption consumables; verify compatibility with serum/antibiotics/surfactants in advance.
FAQ
Q: What are the benefits of Semax peptide?
A: Commonly observed in studies: increased BDNF, improved neuroplasticity and learning/memory endpoints, accompanied by anti-inflammatory/antioxidant trends; this does not constitute a medical claim.
Q: Is Semax legal to buy?
A: We only provide research-grade RUO for institutional/corporate laboratories; it must not be used in humans, for diagnostics, or veterinary purposes; please comply with local regulations and import requirements.
Q: Is Semax or Selank better?
A: Different focuses: Semax emphasizes neuroprotection and plasticity (BDNF, ERK/CREB); Selank focuses on stress/anxiety pathways; choose according to your research topic or conduct parallel comparisons.
Q: Is Semax good for ADHD?
A: For research exploration only; it can be used for attention/executive function model assessment; no clinical use or efficacy guarantees are provided.
Q: What purity and QC documents are provided?
A: HPLC ≥99.5%, LC-MS/MS identification; low endotoxin/low TFA optional; COA, chromatogram/MS chromatogram, and SDS are included.
Q: How to reconstitute and store?
A: Reconstitute with sterile water or PBS; aliquot the stock solution into 1–5 mg/mL containers; store at -20°C to -80°C protected from light, avoiding repeated freeze-thaw cycles.
Hot Tags: semax peptide, China semax peptide manufacturers, suppliers, factory, BPC 157 Powder, Survodutide Peptide, Ghrp Peptide, Selank Powder, Peptide SS 31, Thymosin Alpha 1 Peptide
